Activation of free fatty acid receptor 1 improves hepatic steatosis through a p38-dependent pathway

Journal of Molecular Endocrinology

Volumn 53, Issue 2, 2014, Pages 165-174

  Ou, Horng Yih ^a   Wu, Hung Tsung ^a,b   Lu, Feng Hwa ^a   Su, Yu Chu ^c   Hung, Hao Chang ^a   Wu, Jin Shang ^a   Yang, Yi Ching ^a   Wu, Chao Liang ^c   Chang, Chih Jen ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Free fatty acid receptor; Hepatic steatosis; Insulin resistance; P38 MAPK; Sterol regulatory element binding protein

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; G PROTEIN COUPLED RECEPTOR 40; GW 9508; LENTIVIRUS VECTOR; OLEIC ACID; SHORT HAIRPIN RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; 1-(6-((3-METHOXYESTRA-1,3,5(10)-TRIEN-17-YL)AMINO)HEXYL)-1H-PYRROLE-2,5-DIONE; 2 PYRROLIDONE DERIVATIVE; ESTRANE DERIVATIVE; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FATTY LIVER; GENE SILENCING; GENE TARGETING; HEPG2 CELL LINE; LIPID DIET; LIPID LIVER LEVEL; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ADVERSE EFFECTS; AGONISTS; ANIMAL; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; LIPID METABOLISM; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ESTRENES; FATTY LIVER; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; LIPID METABOLISM; MALE; MAP KINASE SIGNALING SYSTEM; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOINOSITIDE PHOSPHOLIPASE C; PROTEIN KINASE C; PYRROLIDINONES; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84907990513     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-14-0003     Document Type: Article

References (24)

1. Christiansen E, Hansen SV, Urban C, Hudson BD, Wargent ET, Grundmann M, Jenkins L, Zaibi M, Stocker CJ, Ullrich S et al. 2013 Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Medicinal Chemistry Letters 4 441-445. (doi:10.1021/ml4000673)
2. Feng DD, Luo Z, Roh SG, Hernandez M, Tawadros N, Keating DJ & Chen C 2006 Reduction in voltage-gated KC currents in primary cultured rat pancreatic b-cells by linoleic acids. Endocrinology 147 674-682. (doi:10.1210/en.2005-0225)
3. Ferre P & Foufelle F 2010 Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes, Obesity &Metabolism 12 83-92. (doi:10.1111/j.1463-1326.2010.01275.x)
4. Hara T, Hirasawa A, Ichimura A, Kimura I & Tsujimoto G 2011 Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. Journal of Pharmaceutical Sciences 100 3594-3601. (doi:10.1002/jps.22639)
5. Ito R, Tsujihata Y, Matsuda-Nagasumi K, Mori I, Negoro N & Takeuchi K 2013 TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and b-cell dysfunction in Zucker diabetic fatty rats. British Journal of Pharmacology 170 568-580. (doi:10.1111/bph.12297)
6. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H et al. 2003 Free fatty acids regulate insulin secretion from pancreatic b cells through GPR40. Nature 422 173-176. (doi:10.1038/nature01478)
7. Kaku K, Araki T & Yoshinaka R 2013 Randomized, double-blind, doseranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 36 245-250. (doi:10.2337/dc12-0872)
8. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C & Poitout V 2008 The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57 2432-2437. (doi:10.2337/db08-0553)
9. Lan H, Hoos LM, Liu L, Tetzloffl G, Hu WW, Abbondanzo SJ, Vassileva G, Gustafson EL, Hedrick JA & Davis HR 2008 Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 57 2999-3006. (doi:10.2337/db08-0596)
10. Lewis JR & Mohanty SR 2010 Nonalcoholic fatty liver disease: a review and update. Digestive Diseases and Sciences 55 560-578. (doi:10.1007/s10620-009-1081-0)
11. Mieczkowska A, Basle MF, Chappard D & Mabilleau G 2012 Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. Journal of Biological Chemistry 287 23517-23526. (doi:10.1074/jbc.M111.324814)
12. Ou HY, Wu HT, Hung HC, Yang YC, Wu JS & Chang CJ 2013 Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity. American Journal of Physiology. Endocrinology and Metabolism 304 E668-E676. (doi:10.1152/ajpendo.00419.2012)
13. Owen JL, Zhang YY, Bae SH, Farooqi MS, Liang GS, Hammer RE, Goldstein JL & Brown MS 2012 Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase. PNAS 109 16184-16189. (doi:10.1073/pnas.1213343109)
14. Seljeset S & Siehler S 2012 Receptor-specific regulation of ERK1/2 activation by members of the “free fatty acid receptor” family. Journal of Receptors and Signal Transduction 32 196-201. (doi:10.3109/10799893.2012.692118)
15. Spector AA 1975 Fatty-acid binding to plasma albumin. Journal of Lipid Research 16 165-179.
16. Suh HN, Huong HT, Song CH, Lee JH & Han HJ 2008 Linoleic acid stimulates gluconeogenesis via Ca2C/PLC, cPLA2, and PPAR pathways through GPR40 in primary cultured chicken hepatocytes. American Journal of Physiology. Cell Physiology 295 C1518-C1527. (doi:10.1152/ajpcell.00368.2008)
17. Tanaka H, Yoshida S, Minoura H, Negoro K, Shimaya A, Shimokawa T & Shibasaki M 2014 Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. Life Sciences 94 115-121. (doi:10.1016/j.lfs.2013.11.010)
18. Wang SR, Pessah M, Infante J, Catala D, Salvat C & Infante R 1988 Lipid and lipoprotein metabolism in hep-G2 cells. Biochimica et Biophysica Acta 961 351-363. (doi:10.1016/0005-2760(88)90082-3)
19. Wang CR, Shiau AL, Chen SY, Cheng ZS, Li YT, Lee CH, Yo YT, Lo CW, Lin YS, Juan HY et al. 2010 Intra-articular lentivirus-mediated delivery of galectin-3 shRNA and galectin-1 gene ameliorates collagen-induced arthritis. Gene Therapy 17 1225-1233. (doi:10.1038/gt.2010.78)
20. Wu HT, Chen W, Cheng KC, Ku PM, Yeh CH & Cheng JT 2012 Oleic acid activates peroxisome proliferator-activated receptor d to compensate insulin resistance in steatotic cells. Journal of Nutritional Biochemistry 23 1264-1270. (doi:10.1016/j.jnutbio.2011.07.006)
21. Wu HT, Lu FH, Ou HY, Su YC, Hung HC, Wu JS, Yang YC, Wu CL & Chang CJ 2013 The role of Hepassocin in the development of non-alcoholic fatty liver disease. Journal of Hepatology 59 1065-1072. (doi:10.1016/j.jhep.2013.06.004)
22. Xiong Y, Collins QF, An J, Lupo E, Liu HY, Liu DL, Robidoux J, Liu ZQ & CaoWH2007 p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis. Journal of Biological Chemistry 282 4975-4982. (doi:10.1074/jbc.M606742200)
23. Zhang Y, Xu M, Zhang S, Yan L, Yang C, Lu W, Li Y & Cheng H 2007 The role of G protein-coupled receptor 40 in lipoapoptosis in mouse b-cell line NIT-1. Journal of Molecular Endocrinology 38 651-661. (doi:10.1677/JME-06-0048)
24. Zhao YF, Wang L, Zha D, Qiao L, Lu L, Yu J, Qu P, Sun Q, Qiu J & Chen C 2013 GW9508 inhibits insulin secretion by activating ATP-sensitive potassium channels in rat pancreatic b-cells. Journal of Molecular Endocrinology 51 69-77. (doi:10.1530/JME-13-0019)